Project Grant DP2AI184637
Award Date
6/6/25
Completion Date
5/31/30
Dollars Obligated
$486K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $194,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project aims to use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent (the "shock") and then target the reactivated cells for elimination using adeno-associated virus (AAV) vectors expressing broadly...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding the development of a non-viral gene therapy to sustain therapeutic levels of the eCD4-Ig protein. Emmune Inc., a biotechnology company, received $919,501 to conduct basic science experiments and enhance the efficiency of gene transfer into skeletal muscle. The goal is to create a long-acting, one-time intramuscular...
This $2,688,880 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key research objectives include: Comprehensively testing the effects of IL-15/IL-15RA therapy combined with TGF-beta pathway blockade on different T and NK cell subsets during chronic SIV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,737 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Yale University. The grant, titled "CAPSID-ENGINEERED AAV VECTORS WITH BREC1-BASED GENE THERAPEUTICS FOR INACTIVATING THE HIV RESERVOIR", aims to develop gene therapy approaches to eliminate the HIV reservoir in people living with HIV. Specifically, the project will engineer adeno-associated viral (AAV) vectors to...
This $502,861 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of the human protein PCIF1 in regulating interactions between the HIV virus and host cells. The key objectives are to: 1) Define the dynamics and mapping of human RNA methylome modifications induced by HIV infection and methamphetamine exposure; 2) Determine how HIV alters...
This federal Project Grant award, valued at $489,500.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research at The Children's Hospital of Philadelphia (CHOP) to better understand the characteristics of the intact HIV reservoir, which is a major barrier to curing HIV. The research aims to identify the distinct features of cells with intact HIV provirus, including...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Southwestern Medical Center in Dallas, Texas. The $234,113 award, effective August 1, 2024 through June 30, 2026, will fund research to characterize the epigenetic regulation of HIV-1 proviruses and explore novel therapeutic approaches for eliminating the persistent HIV reservoir. The project aims to study...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University in the amount of $800,389.00 on June 4, 2025. The grant supports research to evaluate the safety and therapeutic potential of a novel strategy to achieve a cure for HIV infection. The key objectives are to: Comprehensively test the effects of IL-15/IL-15RA-FC therapy combined with TGF-beta blockade on different T...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $694,301 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant aims to define the mechanisms underlying the protective outcomes observed in the ECLEAR Phase 1b/2a clinical trial, which found that administration of the HIV-env specific broadly neutralizing antibody 3BNC117...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,256 to support research aimed at eliciting broadly neutralizing antibodies (bNAbs) against HIV-1 through immunization approaches. The research, led by MD-PhD student Ashwin Skelly under the mentorship of Drs. Beatrice Hahn and Amelia Escolano at the University of Pennsylvania and Wistar Institute, will...